🌍·1d agodiscovery
Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer
Publisher
E
EurekAlert!
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- EurekAlert!
- Region
- Global
- Scope
- discovery
- Published
- September 12, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: EurekAlert!
Scope: discovery
Related coverage
More related coverage
guardian.ng/3h ago
Makinde, others to grace PSN Oyo 2026 World Pharmacists Day
timothysykes.com/3h ago
DBVT Slides As DBV Technologies Leads European Biotech Declines
TheStreet Pro/3h ago
How to Trade This $2 Billion Biotech Name Moving Quickly Toward Profit
MarketBeat/3h ago